Status:
COMPLETED
Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy
Lead Sponsor:
Children's Mercy Hospital Kansas City
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Growth Hormone Deficiency
Eligibility:
MALE
18-25 years
Brief Summary
The purpose of this study is to compare the cardiovascular risks of growth hormone deficient young adult males who have completed growth hormone therapy to healthy young adult males.
Detailed Description
Adults with growth hormone deficiency are at risk for cardiovascular disease. What age this begins is not known. The objectives of this study are to compare the following measurements between growth ...
Eligibility Criteria
Inclusion
- Growth Hormone Deficient
- Males, 18-25 years old
- Completed growth hormone therapy approximately 3-5 years prior to study enrollment
- History of multiple pituitary hormone deficiencies or growth hormone stimulation test \<7 at initiation of growth hormone therapy
- Healthy Control
- Males, 18-25 years old
- No confirmed endocrine diagnosis including Diabetes and thyroid disorders
- BMI - z-score within 2 SD of mean
Exclusion
- Known risk factors for cardiovascular disease (eg tobacco use, hypertension, diabetes)
- Family history of early cardiovascular disease (myocardial infarction or stroke \<55years of age) in first degree family members
- Any implanted device
- Medication known to interfere with glucose or lipid metabolism or to influence blood pressure
- Chronic organ illness (eg severe asthma, hepatic or nephritic conditions)
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00711061
Start Date
June 1 2008
End Date
February 1 2009
Last Update
February 10 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Childrens Mercy Hospitals and Clinics
Kansas City, Missouri, United States, 64108